Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chart: PARTNER II: Ready To Launch

This article was originally published in The Gray Sheet

Executive Summary

Following well-received one-year results from its PARTNER study, Edwards announced Sept. 23 that it has finally received FDA go-ahead to begin the U.S. pivotal trial of its next-generation Sapien XT transcatheter valve.

You may also be interested in...

FDA OKs Sapien Valve As Pivotal Trial Control Prior To Marketing Approval

Edwards Lifesciences says FDA will support use of the firm's investigational Sapien transcatheter aortic heart valve as a control treatment in an upcoming trial of the firm’s next-generation Sapien XT.

Edwards' Full Euro Launch Of Sapien XT Valve Helps Boost Numbers

The European launch of Edwards Lifesciences' Sapien XT transcatheter valve drove a healthy jump in second-quarter revenue

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts